Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: An outcome study

Folia Biologica

Volumn 49, Issue 5, 2003, Pages 183-190

  Huland, Edith ^a   Burger, A ^b   Fleischer, J ^c   Fornara, P ^d   Hatzmann, E ^j   Heidenreich, A ^e   Heinzer, H ^a   Heynemann, H ^d   Hoffmann, L ^f   Hofmann, R ^e   Huland, H ^a   Kampfer I ^f   Kindler, M ^b   Kirchner, H ^g   Mehlhorn, G ^h   Moniak, T H ^h   Rebmann, U ^h   Roigas, J ⁱ   Schneider, T H ^d   Schnorr, D ⁱ   Schmitz, H J ^c   Wenisch, R ^c   Varga, Z ^e   Vinke, J ^j   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Onkologische Schwerpunktpraxis   (Germany)

^c St Carolus Krankenhaus   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f Waldklinikum GmbH   (Germany)

^g Klinikum Siloah   (Germany)

^h Diakonissenkrakenhaus   (Germany)

ⁱ HUMBOLDT UNIVERSITY   (Germany)

^j Chiron BV   (Netherlands)

more..

Author keywords

Aerosol; Inhalation; Interleukin 2; Local therapy; Lung metastasis; Renal cancer

Indexed keywords

ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; INHALER; INJECTION SITE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PROBABILITY; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME;

EID: 10744222612     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Atzpodien, J., Korfer, A., Franks, C. R., Poliwoda, H., Kirchner, H. (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335, 1509-1512.
2. Atzpodien, J., Kirchner, H., deMulder, P., Bodenstein, H., Oliver, T., Palmer, P. A., Franks, C. R., Poliwoda, H. (1993) Subcutaneous recombinant interleukin-2 and α-interferon in patients with advanced renal cell carcinoma: results of a multicenter phase II study. Cancer Biother. 8, 289-300.
3. Atzpodien, J., Lopez Hänninen, E., Kirchner, H., Bodenstein, H., Pfreundschuh, M., Rebmann, U., Metzner, B., Illiger, H. J., Jakse, G., Niesel, T., Scholtz, H.-J., Wilhelm, S. (1995) Multiinstitutional home-therapy trial of recombinant interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13, 497-501.
4. Bukowski, R. M. (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198-1220.
5. Buzio, C., Palma, G. de., Passalacqua, R., Potenzoni, D., Ferrozzi, F., Cattabiani, M. A., Manenti, L., Borghetti, A. (1997) Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br. J. Cancer 76, 541-544.
6. Cheever, M. A., Greenberg, P. D., Fefer, A., Gillis, S. (1982) Augmentation of the anti-tumour therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2. J. Exp. Med. 155, 968-980.
7. Clark, J. I., Gaynor, E., Martone, B. (1999) Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinoma. Clin. Cancer Res. 5, 2374-2380.
8. Debatin, K. M., Woodroofe, C., Lahm, H., Fischer, J., Falk, W. (1989) Lack of interleukin-2 (IL-2) dependent growth of TAC positive T-ALL/NHL cells is due to the expression of only low affinity receptors of IL-2. Leukemia 8, 566-571.
9. deKernion, J. B., Sarna, G., Figlin, R., Lindner, A., Smith, R. B. (1983) The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol. 130, 1063-1066.
10. Elson, P. J., Witte, R. S., Trump, D. L. (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48, 7310-7313.
11. Figlin, R., Gitlitz, B., Franklin, J., Dorey, F., Moldawer, N., Rausch, J., Kernion, J. de., Belldegrun, A. (1997) Interleukin 2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J. Sci. Am. 3, S92-S97.
12. Foa, R., Guarini, A., Gansbacher, B. (1992) IL-2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 6, 992-998.
13. Fossa, S. D., Kramar, A., Droz, J. P. (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur. J. Cancer 30A, 1310-1314.
14. Goepel, M., Rubben, H. (1991) Adjuvant therapy in renal cancer. World J. Urol. 9, 232-236.
15. Grootendorst, P. V., Feeny, D. H., Furlong, W. (1997) Does it matter whom and how you ask? Inter- and intra-rater agreement in the Ontario Health Survey. J. Clin. Epidemiol. 50, 127-135.
16. Heidenreich, A., Neubauer, S. (1999) Interleukin-2 inhalation therapy in pulmonary metastases of renal cell cancer - Cologne experience. Anticancer Res. 19, 2003-2004.
17. Heinzer, H., Mir, T. S., Huland, E., Huland, H. (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J. Clin. Oncol. 17, 3612-3620.
18. Huland, E. (2001) Interleukin-2 and cancer - physiological and pharmacological uses. Folia Biol. (Praha) 47, 111-112.
19. Huland, E., Huland, H., Heinzer, H. (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol. 147, 344-348.
20. Huland, E., Heinzer, H., Mir, T. S., Huland, H.(1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience. Cancer J Sci. Am. 3, S98-S105.
21. Huland, E., Heinzer, H., Huland, H. (1999) Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res. 19, 2679-2683.
22. Huland, E., Heinzer, H., Huland, H. (2000a) A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma. Folia Biol. (Praha) 46, 241-250.
23. Huland, E., Heinzer, H., Huland, H., Yung, R. (2000b) Overview of interleukin-2 inhalation therapy. Cancer J. Sci. Am. 6, S104-S112.
24. Huland, E., Heinzer, H., Timm, S., Aalamian, M., Huland, H. (2002) Immunotherapy for metastatic renal-cell carcinoma in Germany: a nationwide survey. Urologe A 41, 282-287.
25. Jones, M., Philip, T., Palmer, P., von der Maase, H., Vinke, J., Elson, P., Franks, C. R., Selby, P. (1993) The impact of interieukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 4, 275-288.
26. Kolitz, J. E., Mertelsmann, R. (1991) The immunotherapy of human cancer with interleukin-2: present status and future directions. Cancer Invest. 9, 529-542.
27. Lee, R. E., Lotze, M. T., Skibber, J. M. (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol. 7, 7-20.
28. Lorenz, J., Wilhelm, K., Kessler, M. (1996) Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin. Cancer Res. 2, 1115-1122.
29. Motzer, R. J., Mazumdar, M., Bacik, J. (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 1928-1935.
30. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., Ferrara, J. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. OncoL 17, 2530-2540.
31. Nakamoto, T., Kasaoka, Y., Mitani, S., Usui, T. (1997) Inhalation of interleukin-2 combined with subcutaneous administration of interferon for the treatment of pulmonary metastases from renal cell carcinoma. Int. J. Urol. 4, 343-348.
32. Négrier, S., Philip, T., Stoter, G., Fossa, S. D., Janssen, S., Iacone, A., Cleton, F. S., Eremin, O., Israel, L., Jasmin, C., Rugarli, C., von der Maasse, H. (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J. Cancer Clin. Oncol. 25, S21-S28.
33. Oldham, R. K. (1984) Biological response modifiers program workshop, "In vivo-effects of IL-2". J. Biol. Response Modif. 3, 455-532.
34. Palmer, P. A., Vinke, J., Philip, T., Negrier, S., Atzpodien, J., Kirchner, H., Oskam, R., Franks, C. R. (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann. Oncol. 3, 475-480.
35. Palmer, P. A., Atzpodien, J., Philip, T., Negrier, S., Kirchner, H., von der Maase, H., Geertsen, P., Evers, P., Loriaux, E., Oskam, R., Roest, G., Vinke, J., Franks, C. R. (1993) A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother 8, 123-136.
36. Patel, N. P., Lavengood, R. W. (1977) Renal cell cancer: natural history and results of treatment. J. Urol. 119, 722-726.
37. Piltz, S., Meimarakis, G., Wichmann, M., Hatz, R., Schildberg, F., Fuerst, H. (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann. Thorac. Surg. 73, 1082-1087.
38. Pizza, G., De Vinci, C., Lo, C. G. (2001) Immunotherapy of metastatic kidney cancer. Int. J. Cancer 94, 109-120.
39. Ravaud, A., Négrier, S., Cany, L., Merrouche, Y., Guillou, M. Le., Blay, J. Y., Clavel, M., Gaston, R., Oskam, R., Philip, T. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J. Cancer 69, 1111-1114.
40. Roigas, J. (1990,) Inhalation of interleukin-2 as second-line treatment: Charité experience. Anticancer Res. 19, 2010-2011.
41. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with cancer. N. Eng. J. Med. 313, 1485-1492.
42. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Abersold, P. M., Lineham, W. M, (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
43. Rosenberg, S. A., Yang, J. C., Topalian, S. L. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913.
44. Sosman, J. A., Kohler, P. C., Hank, J. A. (1988) Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. 80, 1451-1461.
45. Stahl, M., Wilke, H.-J., Seeber S., Schmoll, H.-J. (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin. Oncol. 19, S70-S79.
46. West, W. H., Tauerm, K. W., Yanellim, J. R., Marshall, G. D., Orr, D.W., Thurman, G. B., Oldham, R. K. (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med. 316, 898-905.
47. Zissel, G., Aulitzky, W. E., Lorenz, J., Huber, C., Muller Quernheim, J. (1996) Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunol. Immunother 42, 122-126.